LATEST RESEARCH NEWS ON TABLETS: FEB-2020

ORODISPERSIBLE TABLETS: AN OVERVIEW

Oral drug delivery remains the preferred route for administration of various drugs. Recent developments in the technology have prompted scientists to develop orally disintegrating tablets (ODTs) with improved patient compliance and convenience. ODTs are solid unit dosage forms, which disintegrate or dissolve rapidly in the mouth without chewing and water. Orally disintegrating tablets provide an advantage particularly for pediatric and geriatric populations who have difficulty in swallowing conventional tablets and capsules.This review describes the various formulation aspects, disintegrants employed and technologies developed for ODTs, along with various excipients, evaluation tests, marketed formulations,
and drugs explored in this field. [1]

Abuse resistant tablets

This invention relates to an abuse resistant tablet containing two or more layers having one or more drugs and one or more gelling agents and its preparation. The drug(s) and gelling agent(s) are in separate layers of the tablet. The multilayer tablet is particularly suitable for the administration of drugs prone to abuse by unauthorized parenteral administration such as analgesics, hypnotics, and anxiolytics. [2]

 

Fast dispersible ibuprofen tablets

Fast dispersible tablets disintegrate either rapidly in water, to form a stabilized suspension, or disperse instantaneously in the mouth to be swallowed without the aid of water. [3]

Preparation of Metformin Hydrochloride Extended Release Matrix Tablets by Direct Compression Method and Its In vitro Evaluation

Aims: Metformin Hydrochloride, a biguanide, is an orally active antihyperglycemic agent, used in the treatment of non-insulin dependent diabetes mellitus (NIDDM). It has relatively short plasma half life, low absolute bioavailability. Extended release formulation of Metformin Hydrochloride by direct compression method has significant challenges due to its poor inherent compressibility and high dose. The aim of this study was to develop extended release tablets of Metformin Hydrochloride by direct compression method and In vitro evaluation. [4]

Segregated Delivery of Rifampicin and Isoniazid from Fixed Dose Combination Bilayer Tablets for the Treatment of Tuberculosis

Aims: Develop an anti-tuberculosis (TB) Fixed Dose Combination (FDC) tablet containing an immediate release layer (IRL) composed of both rifampicin (RIF) and pyrazinamide (PYR) and a retarded release layer (RRL) comprised of isoniazid (INH) which would allow segregated delivery of RIF and INH. [5]

Reference

[1] Bandari, S., Mittapalli, R.K. and Gannu, R., 2014. Orodispersible tablets: An overview. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm2(1).

[2] Bastin, R.J. and Lithgow, B.H., Aventis Pharma Ltd, 2001. Abuse resistant tablets. U.S. Patent 6,309,668.

[3] Schiermeier, S. and Schmidt, P.C., 2002. Fast dispersible ibuprofen tablets. European journal of pharmaceutical sciences15(3), pp.295-305.

[4]  Hasan, M.R., Hossen, M.A., Roy, A., Islam, T. and Pathan, M.S.I., 2014. Preparation of metformin hydrochloride extended release matrix tablets by direct compression method and its in vitro evaluation. Journal of Pharmaceutical Research International, pp.2679-2693.

[5] Silva, A.M., Abrahim-Vieira, B., do Carmo, F.A., do Amaral, L.H., Silva, L.C., Escudini, C.S., Lopes, M.A., Sousa, V.P., Castro, H.C., Veiga, F. and Rodrigues, C.R., 2014. Segregated delivery of rifampicin and isoniazid from fixed dose combination bilayer tablets for the treatment of tuberculosis. Journal of Pharmaceutical Research International, pp.1781-1801.

 

Editor

Leave a Reply

Your email address will not be published.